A LEADERSHIP TEAM WITH DECADES OF EXPERIENCE INBIOTECH INNOVATION AND VALUE CREATION
Combining deep expertise in sourcing and evaluating investment opportunities, deal-making,executing streamlined development programs, and venture exits
ABOUT US
We identify breakthrough life science investment opportunities and found, fund, manage and exit biotech companies at IND stage
Systematic Innovation Sourcing
• Access to discoveries from universities and global research networks
Data-Driven Investment Selection
• Taking advantage of BSV’s proprietary analytics built from 25 years of project evaluation, complemented by AI-powered analytics
Capital-Efficient Development
• Focus on early development and IND-stage exits with high ‘return to risk’ ratios
Preferred Partner for Innovators and Academia
• Highly experienced team of seasoned industry experts
Dr. Sabine Bernotat-Danielowski, MBA, CDO
R&D and portfolio management leader at Big Pharma
25 years R&D management experience in several therapeutic areas in the EU, USA, India & Japan
- Daiichi Sankyo: UK-based Managing Director Drug Development Ph1 to approval, EU & India,
US-based Head Portfolio Management - Merck KGaA: Global Head Project Evaluation and Portfolio Management
- Various roles in R&D from target identification to approval
- MS Biology University of Berlin , PhD Max-Planck Institute for Biophysics, Postdoc Max-Planck-Institute for Cardiology , MBA Hult-Ashridge Management School, UK
Dr. Joachim M. Greuel, MBA, CEO
25+ years experience evaluating life-science investment opportunities
25 years experience in the assessment and valuation of life-science investment opportunities
- Bioscience Valuation, Managing Director
- IE Business School, Academic Director, Master in Biotechnology Management Program
- IE Business School, Professor of Healthcare Management & Finance
- New Medical Technologies Venture Fund, Investment Manager
- Bayer AG, Lead Neurophysiological Research
- MS Biology University of Marburg, PhD Max-Planck Institute for Brain Research, MBA Wharton School, Univ. of Pennsylvania
Dr. Dirk Kreder, MBA, CFO
Proven ability to drive value creation through successful exits
25 years experience in global R&D management, regulatory clearance & launch, as well as board experience in pharma, biotech, and medical device companies
- Brought several high-value products to global markets, including the US, EU and Asia
- Founded seven companies to date, exited four
- Last permanent position as Founder and CEO of sister companies anteris medical GmbH and anteris helvetia AG
- Founder of, and investor through, ALOM Ventures GmbH
- Highly networked in the US, Europe and Asia
- Diploma in Biology, PhD in Immunology,
International Executive MBA from EURO*MBA consortium
Dr. Michael Ruppert, MBA, CBO
Experience in licensing and structuring partnerships supported by a global network across pharma and academia
>20 years experience in international business development for pharma and biotech companies and university spin-offs
- Long-standing track record as a seasoned deal-maker in the life science industry
- >30 clients over last 15 years as a Consultant, incl. Sandoz, Mundipharma, Hikma and Tolmar
- Last permanent position as Head of Business Development & Alliance Management at MediGene AG
- Highly networked in the US, Europe and Asia, as well as with academic centers and incubators
- Diploma in Biology, PhD in Immunology, MBA, Manager Market Access